Vokietija – Inžineriniai tyrimai – IIT study CLEAR "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)"

Vokietija – Inžineriniai tyrimai – IIT study CLEAR "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)"

I dalis: Perkančioji organizacija

I.1) Pavadinimas ir adresai:

Oficialus pavadinimas: Universitätsklinikum Münster
Adresas: Albert-Schweitzer-Campus 1 Gebäude A3
Miestas: Münster
Pašto kodas: 48149
Šalis: Vokietija
Asmuo ryšiams:
El-paštas: vvgm@ukmuenster.de
Interneto adresas (-ai):
Pagrindinis adresas:

II dalis: Objektas

II.1.1) Pavadinimas:

IIT study CLEAR "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)"
Nuorodos numeris: GBBM20241021LG_1

II.1.2) Pagrindinis BVPŽ kodas:

71335000 Inžineriniai tyrimai ;

II.1.3) Sutarties tipas:

Kita

II.1.4) Trumpas aprašymas:

The IIT (Investigator Initiated Trial) study CLEAR "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)" should take place in 26 trial sites in Germany and 4 trial sites in Italy. The University of Münster acts as sponsor of the clinical trial CLEAR according to Article 2 No. 14 Regulation (EU) 536/2014 (CTR). For the conduct of the study in Italy, we would like to transfer the following tasks in the areas of project management, trial start-up, monitoring and quality assurance to another institution in Italy. A synopsis of the study is attached to this tender as Appendix 1. A framework agreement will be concluded afterwards.

II.2) Aprašymas:

II.2.1) Kitas (-i) šio pirkimo BVPŽ kodas (-ai):

71335000 Inžineriniai tyrimai